Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AML-BFM 2004
NCT00111345Phase 3Unknown
- Sponsor
- Universitätsklinikum Münster
- Start
- Mar 2004
- Primary completion
- Mar 2012
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of liposomal daunorubicin and cladribine in acute myeloid leukemia (AML) (4 arms), sponsored by Universitätsklinikum Münster. Primary endpoints: Event-Free Survival at 5 years, Overall Survival at 5 years and 1 more. Status: unknown.
02
Drugs
liposomal daunorubicincladribine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00111345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00111345.